A Phase II Randomized Study of Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma
Pembrolizumab is a new type of drug for mesothelioma (immunotherapy). Laboratory tests show
that this drug works by helping improve the body's immune response to help fight cancer.
Pembrolizumab may help the immune system to recognize cancer cells and slow down the growth
and/or spreading of cancer.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society